Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A.
Jimeno A, et al. Among authors: ji rr.
Invest New Drugs. 2023 Apr;41(2):284-295. doi: 10.1007/s10637-023-01342-x. Epub 2023 Mar 3.
Invest New Drugs. 2023.
PMID: 36867316
Free PMC article.
Clinical Trial.